Dr. Chris Nirschl, Katie Yost, and Tom Nirschl (Immunologists) #7

A cancer immunologist by training, Dr. Christopher Nirschl received his PhD from the Johns Hopkins School of Medicine in Immunology in 2015, and completed a postdoctoral fellowship at the Brigham and Women’s Hospital in association with Harvard Medical School. He has been studying the interactions between cancer and the immune system for over a decade, and is also one of the inventors of the anti-TIGIT antibody ASP8374/PTZ-201 which is currently in clinical trials. Doctor Nirschl was a part of the 5 person Immunology team at Potenza Therapeutics, which was acquired by Astellas Pharma for over 100 million dollars in December 2019. Currently, Doctor Nirschl is an Immunologist at Werewolf Therapeutics in Massachusetts, where he lives with his wife and two children.

Katie is a Cancer Biology PhD candidate at Stanford University where she studies tumor and immune cell dynamics during immunotherapy. Her recent work has applied single cell RNA and T cell receptor sequencing to identify to origin of immunotherapy-responsive T cells during checkpoint blockade therapy. Prior to graduate school, she studied telomere maintenance in osteosarcoma as a post-baccalaureate fellow at the National Cancer Institute.

Tom is a 3rd year doctoral candidate in the immuno-oncology laboratories of Dr. Jelani Zarif Ph.D. and Dr. Andrew Pardoll M.D.,Ph.D., investigating the therapeutic benefit of targeting the PI3Kgamma signaling pathway in protumorigenic M2-tumor associated macrophages (TAMs) in the setting of prostate cancer. Previously he worked for 4 years in the laboratory of Dr. Charles Drake M.D.,Ph.D. investigating the of tumor infiltrating lymphocytes (TILs) isolated from primary human tumor specimens.

@worldxppodcast Instagram - https://bit.ly/3eoBwyr
@worldxppodcast Twitter - https://bit.ly/2Oa7Bzm

Spotify - http://spoti.fi/3sZAUTG
Apple Podcasts - http://apple.co/30uGTny
Google Podcasts - http://bit.ly/3v8CF2U
Anchor - http://bit.ly/3qGeaH7
YouTube - http://bit.ly/3rxDvUL #longformpodcast #podcasts #podcaster #newpodcast #podcastshow #podcasting #newshow